Avidity Biosciences

Avidity, founded in 2013 and located in California, USA, is a privately owned biotechnology company. Avidity’s extensive experience in oligonucleotide therapeutics, RNA process regulation, antibody engineering, conjugation, and drug delivery technologies has laid the foundation for the company to address key limitations in oligonucleotide therapies. With its deep expertise in this field and systematic application in the design and development of candidate products, Avidity has successfully built the AOC platform. The company is also a pioneer in the research and development of Antibody Oligonucleotide Conjugates (AOC).Avidity is advancing therapeutic programs targeting rare muscle diseases and other serious conditions. Its pipeline includes AOC1001, a candidate for treating rare monogenic muscle diseases. AOC combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide-based treatments, overcoming barriers that have hindered oligonucleotide delivery and targeted genetic drivers of disease. Using AOC, new potential for RNA therapies can be unlocked by effectively targeting muscle and immune cells, offering treatment options for rare muscle diseases and other severe conditions.